OT-A-201

N/A

Report date: 2025/05/14 14:17:10

Base Information

Drug NameOT-A-201

Drug Alias NameOT-A-201

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCheckpoint kinase inhibitors

TargetsCheckpoint kinase

Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesOnward Therapeutics SA

China Registration ClassN/A

Develop Information

Active CompaniesOnward Therapeutics SA

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A